Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases

Stem Cell Res Ther. 2024 Oct 31;15(1):390. doi: 10.1186/s13287-024-04007-5.

Abstract

Retinal degenerative diseases are a leading cause of vision loss and blindness globally, impacting millions. These diseases result from progressive damage to retinal pigment epithelial (RPE) cells for which no curative or palliative treatments exist. Cell therapy, particularly RPE transplantation, has emerged as a promising strategy for vision restoration. This review provides a comprehensive overview of the recent advancements in clinical trials related to RPE transplantation. We discuss scaffold-free and scaffold-based approaches, including RPE cell suspensions and pre-organized RPE monolayers on biomaterial scaffolds. Key considerations, such as the form and preparation of RPE implants, delivery devices, strategies, and biodegradability of scaffolds, are examined. The article also explores the challenges and opportunities in RPE scaffold development, emphasising the crucial need for functional integration, immunomodulation, and long-term biocompatibility to ensure therapeutic efficacy. We also highlight ongoing efforts to optimise RPE transplantation methods and their potential to address retinal degenerative diseases.

Keywords: Bruch’s membrane; Cell therapy; Cell transplantation; Macular degeneration; Outer blood-retina barrier; Retinal pigment epithelium; Tissue engineering.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Retinal Degeneration* / therapy
  • Retinal Pigment Epithelium* / cytology
  • Retinal Pigment Epithelium* / metabolism
  • Retinal Pigment Epithelium* / transplantation
  • Tissue Scaffolds / chemistry